These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 7585592)

  • 21. Inhibitors of farnesyl protein transferase and MEK1,2 induce apoptosis in fibroblasts transformed with farnesylated but not geranylgeranylated H-Ras.
    Brassard DL; English JM; Malkowski M; Kirschmeier P; Nagabhushan TL; Bishop WR
    Exp Cell Res; 2002 Feb; 273(2):138-46. PubMed ID: 11822869
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Selective cytotoxicity of farnesylamine to pancreatic carcinoma cells and Ki-ras-transformed fibroblasts.
    Ura H; Obara T; Shudo R; Itoh A; Tanno S; Fujii T; Nishino N; Kohgo Y
    Mol Carcinog; 1998 Feb; 21(2):93-9. PubMed ID: 9496909
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells.
    Bolick SC; Landowski TH; Boulware D; Oshiro MM; Ohkanda J; Hamilton AD; Sebti SM; Dalton WS
    Leukemia; 2003 Feb; 17(2):451-7. PubMed ID: 12592346
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Antitumor activity of ER-51785, a new peptidomimetic inhibitor of farnesyl transferase: synergistic effect in combination with paclitaxel.
    Nakamura K; Yamaguchi A; Namiki M; Ishihara H; Nagasu T; Kowalczyk JJ; Garcia AM; Lewis MD; Yoshimatsu K
    Oncol Res; 2001; 12(11-12):477-84. PubMed ID: 11939411
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Ras CAAX peptidomimetic FTI 276 selectively blocks tumor growth in nude mice of a human lung carcinoma with K-Ras mutation and p53 deletion.
    Sun J; Qian Y; Hamilton AD; Sebti SM
    Cancer Res; 1995 Oct; 55(19):4243-7. PubMed ID: 7671229
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Growth inhibition by the farnesyltransferase inhibitor FTI-277 involves Bcl-2 expression and defective association with Raf-1 in liver cancer cell lines.
    Mazzocca A; Giusti S; Hamilton AD; Sebti SM; Pantaleo P; Carloni V
    Mol Pharmacol; 2003 Jan; 63(1):159-66. PubMed ID: 12488548
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Protein farnesyltransferase inhibitors block the growth of ras-dependent tumors in nude mice.
    Kohl NE; Wilson FR; Mosser SD; Giuliani E; deSolms SJ; Conner MW; Anthony NJ; Holtz WJ; Gomez RP; Lee TJ
    Proc Natl Acad Sci U S A; 1994 Sep; 91(19):9141-5. PubMed ID: 8090782
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Inhibition of farnesyl-protein-transferase in neuroblastoma cells by alpha-hydroxyfarnesylphosphonate.
    Girgert R; Hohnecker A; Wittrock J; Schweizer P
    Anticancer Res; 1999; 19(4B):2959-62. PubMed ID: 10652579
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disruption of oncogenic K-Ras4B processing and signaling by a potent geranylgeranyltransferase I inhibitor.
    Lerner EC; Qian Y; Hamilton AD; Sebti SM
    J Biol Chem; 1995 Nov; 270(45):26770-3. PubMed ID: 7592913
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Selective inhibition of farnesyl-protein transferase blocks ras processing in vivo.
    Gibbs JB; Pompliano DL; Mosser SD; Rands E; Lingham RB; Singh SB; Scolnick EM; Kohl NE; Oliff A
    J Biol Chem; 1993 Apr; 268(11):7617-20. PubMed ID: 8463291
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Farnesyltransferase inhibitors versus Ras inhibitors.
    Gibbs JB; Graham SL; Hartman GD; Koblan KS; Kohl NE; Omer CA; Oliff A
    Curr Opin Chem Biol; 1997 Aug; 1(2):197-203. PubMed ID: 9667853
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of cell growth of human hepatoma cell line (Hep G2) by a farnesyl protein transferase inhibitor: a preferential suppression of ras farnesylation.
    Nagase T; Kawata S; Tamura S; Matsuda Y; Inui Y; Yamasaki E; Ishiguro H; Ito T; Matsuzawa Y
    Int J Cancer; 1996 Mar; 65(5):620-6. PubMed ID: 8598313
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Resistance of a variant ras-transformed cell line to phenotypic reversion by farnesyl transferase inhibitors.
    Prendergast GC; Davide JP; Lebowitz PF; Wechsler-Reya R; Kohl NE
    Cancer Res; 1996 Jun; 56(11):2626-32. PubMed ID: 8653708
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The farnesyl transferase inhibitor SCH 66336 induces a G(2) --> M or G(1) pause in sensitive human tumor cell lines.
    Ashar HR; James L; Gray K; Carr D; McGuirk M; Maxwell E; Black S; Armstrong L; Doll RJ; Taveras AG; Bishop WR; Kirschmeier P
    Exp Cell Res; 2001 Jan; 262(1):17-27. PubMed ID: 11120601
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia.
    Peters DG; Hoover RR; Gerlach MJ; Koh EY; Zhang H; Choe K; Kirschmeier P; Bishop WR; Daley GQ
    Blood; 2001 Mar; 97(5):1404-12. PubMed ID: 11222387
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Design and in vivo analysis of potent non-thiol inhibitors of farnesyl protein transferase.
    Anthony NJ; Gomez RP; Schaber MD; Mosser SD; Hamilton KA; O'Neil TJ; Koblan KS; Graham SL; Hartman GD; Shah D; Rands E; Kohl NE; Gibbs JB; Oliff AI
    J Med Chem; 1999 Aug; 42(17):3356-68. PubMed ID: 10464022
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Inhibition of tumor cell growth by monoterpenes in vitro: evidence of a Ras-independent mechanism of action.
    Karlson J; Borg-Karlson AK; Unelius R; Shoshan MC; Wilking N; Ringborg U; Linder S
    Anticancer Drugs; 1996 Jun; 7(4):422-9. PubMed ID: 8826611
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A cell-based radioligand binding assay for farnesyl: protein transferase inhibitors.
    Lobell RB; Davide JP; Kohl NE; Burns HD; Eng WS; Gibson RE
    J Biomol Screen; 2003 Aug; 8(4):430-8. PubMed ID: 14567795
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Antitumor activity of SCH 66336, an orally bioavailable tricyclic inhibitor of farnesyl protein transferase, in human tumor xenograft models and wap-ras transgenic mice.
    Liu M; Bryant MS; Chen J; Lee S; Yaremko B; Lipari P; Malkowski M; Ferrari E; Nielsen L; Prioli N; Dell J; Sinha D; Syed J; Korfmacher WA; Nomeir AA; Lin CC; Wang L; Taveras AG; Doll RJ; Njoroge FG; Mallams AK; Remiszewski S; Catino JJ; Girijavallabhan VM; Bishop WR
    Cancer Res; 1998 Nov; 58(21):4947-56. PubMed ID: 9810004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Preclinical and clinical pharmacodynamic assessment of L-778,123, a dual inhibitor of farnesyl:protein transferase and geranylgeranyl:protein transferase type-I.
    Lobell RB; Liu D; Buser CA; Davide JP; DePuy E; Hamilton K; Koblan KS; Lee Y; Mosser S; Motzel SL; Abbruzzese JL; Fuchs CS; Rowinsky EK; Rubin EH; Sharma S; Deutsch PJ; Mazina KE; Morrison BW; Wildonger L; Yao SL; Kohl NE
    Mol Cancer Ther; 2002 Jul; 1(9):747-58. PubMed ID: 12479371
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.